Trial · NCT05934110
Study Exploring the Supportive Effect of Acarbose in Weight Management
NCT05934110, Phase 2, Unknown, Empros Pharma AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Exploring the Supportive Effect of Acarbose in Weight Management. Trials, record NCT05934110. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05934110
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Exploring the Supportive Effect of Acarbose in Weight Management
- NCT number
- NCT05934110
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 320 participants, estimated
- Lead sponsor
- Empros Pharma AB
- Conditions
- Overweight or Obesity
- Interventions
- EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,, EMP16-60/20, Placebo
- First posted
- 2023-07-06
- Last updated
- 2024-02-20
- Other registries' IDs
- eudract:2022-003320-40
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relative (%) change from baseline in body weight at week 26 | Baseline and week 26 | Efficacy endpoints |
| Primary | Proportion of participants with ≥5% decrease in body weight at week 26 [Please note: This is an FDA required outcome, cannot use "change"] | Baseline and week 26 | Efficacy endpoints |
| Secondary | Relative (%) change from baseline in body weight at week 26 (secondary and exploratory comparisons) | Baseline and week 26 | Efficacy endpoints |
| Secondary | Proportion of participants with ≥5% (secondary and exploratory comparisons) and ≥10% (all comparisons) decrease in body weight at week 18 and week 26 | Baseline, week 18 and 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in body weight at week 26 | Baseline and week 26 | Efficacy endpoints |
| Secondary | Relative (%) change from baseline in body weight during the 26-weeks treatment period | Baseline to week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in body weight during the 26-weeks treatment period | Baseline to week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in body mass index (BMI) measured as weight (kg) divided by height (m) squared | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in waist circumference | Baseline and week 26 | Efficacy endpoints |
| Secondary | Absolute change from baseline in sagittal diameter | Baseline and week 26 | Efficacy endpoints |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05934110
GET https://conductscience.org/api/trials/v1/NCT05934110/registered?page=2